Arcadia Biosciences Announces Second-Quarter And First-Half 2017 Financial Results and Business Highlights

Revenues Up, Expenses and Net Loss Down

DAVIS, Calif. (August 10, 2017) – Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural technology company that creates value for farmers while benefitting the environment and enhancing human health, today released its financial and business results for the second quarter and first half of 2017.

Revenues for the quarter were up 37 percent to $991,000, compared to $721,000 for the second quarter of 2016. The increase reflects higher product sales as well as higher contract and grant revenue, primarily the result of a new agreement. Operating expenses for the second quarter were $4.7 million compared to $5.0 million for the same period in the prior year.

The company’s net loss and net loss attributable to common stockholders in the second quarter of 2017 was $4.0 million, compared to $4.6 million in the comparable period in 2016.

For the first half of 2017, net loss attributable to common stockholders was $8.2 million, an improvement of 16 percent over the comparable period loss of $9.7 million in 2016. Cash on hand and liquid investments at the end of the second quarter totaled $44.1 million.

“Our positive momentum from the first quarter continued in the second quarter with increased revenue, decreased operating costs and a reduced net loss,” said Raj Ketkar, president and CEO of Arcadia. “Together with our global partners, we continue to advance the key products from our yield trait and food ingredient platforms toward commercialization.”

Business and Technology Highlights

Arcadia made the following business and technical achievements during the second quarter of 2017:

  • SONOVA GLA Safflower Oil Approved For Use in Dog Food. After completing its review of Arcadia’s food additive petition, the FDA concluded that the data supports the safety and functionality of GLA safflower oil as a source of omega-6 fatty acids in dry food for adult dogs. The petition will be approved when the final rule is published in the Federal Register. This approval opens up an expanded opportunity for use of SONOVA GLA safflower oil in pet nutrition and demonstrates Arcadia’s strong regulatory capabilities and commitment toward creating the greatest possible value for our entire product portfolio.

  • Eric J. Rey and Gregory D. Waller Join Arcadia Biosciences Board Of Directors. Eric J. Rey and Gregory D. Waller were elected at the company’s annual stockholders meeting to replace directors Vic Knauf, Ph.D., and Rajiv Shah, M.D. Additionally, the board of directors formally elected George F.J. Gosbee as its chair. Gosbee had served as interim chair of the board since November 2016.

Since the close of the second quarter, Arcadia has also announced the following achievements:

  • Arcadia and Dow AgroSciences (DAS) to Collaborate on Improved Wheat Quality Trait. Arcadia and DAS will jointly develop and commercialize a breakthrough improved wheat quality trait in North America. The collaboration leverages Arcadia’s leading non-GM TILLING trait development platform with DAS’ enabling technology platforms, high-quality elite germplasm and global commercial channels.

  • HB4 Stress-Tolerant Soybeans Complete U.S. FDA Safety Review. Through Verdeca, a joint venture with Bioceres, Arcadia completed the FDA safety review for HB4 stress-tolerant soybeans. This allows products derived from the trait to be used commercially in human food and animal feed. This is a major milestone in the development of this trait, which aims to create significant value for soybean growers by bringing yield stability to areas that experience chronic water stress problems.

  • Arcadia’s Water Use Efficiency Trait Completes US Food and Drug Administration Early Food Safety Evaluation (EFSE). The FDA’s EFSE concluded that the functional protein for the WUE trait, isopentenyl transferase (IPT), is safe for humans and animals and would not raise food safety concerns if present in the food supply. This approval is an assurance of safety for WUE crops currently under development and being tested in the field and will expedite the regulatory approvals for this trait. Greenhouse and field trials of the WUE trait have been completed in agronomic crops such as rice, wheat, cotton, peanuts and alfalfa, and Arcadia is currently working with collaborators in rice, potato, sugarcane, cotton and multiple tree species.

  • Amy Yoder Joins Arcadia Biosciences Board of Directors. Yoder is president and CEO of Anuvia Plant Nutrients and the former president and CEO of Arysta LifeScience. She received a bachelor’s degree in agricultural technology and systems management from Michigan State University, with an emphasis in crop and soil science.

Arcadia Biosciences, Inc.

Financial Snapshot


($ in thousands)

Three months ended June 30

Six months ended June 30



Favorable/ (Unfavorable)









Total Revenues









Total Operating Expenses









Loss From Operations









Net Loss and Net Loss Attributable to Common Stockholders










In the second quarter of 2017, revenues were $991,000 compared to revenues of $721,000 in the second quarter of 2016, a 37 percent improvement. The quarter-over-quarter increase was driven by increased product sales and additional revenue from a new contract research agreement in 2017. In the first half of 2017, overall revenues increased to $2.0 million from $1.6 million primarily as a result of the new contract research agreement.

Operating Expenses

In the second quarter of 2017, operating expenses totaled $4.7 million, down from $5.0 million in the first quarter of 2016, a decrease of $282,000 or 6 percent. For the first half of 2017, operating expenses were $9.7 million, compared with $10.8 million during the same period in 2016. Cost of product revenues increased by $40,000 as a result of higher sales when comparing the respective six-month periods. Research and development (R&D) spending decreased by $926,000 and general and administrative (SG&A) expenses decreased by $200,000. Both expense categories had decreases driven primarily by lower salaries and benefits, mainly the result of workforce reductions made during 2016.

Net Loss and Net Loss Attributable to Common Stockholders

Net loss and net loss attributable to common stockholders for the second quarter of 2017 was $4.0 million, or a loss of $0.09 per share, a 12 percent improvement from the $4.6 million loss in the second quarter of 2016. Net loss and net loss attributable to common stockholders for the first half of 2017 was $8.2 million, compared to $9.7 million for the first half of 2016.


Following the close of the second quarter, in July 2017, the Company repaid its outstanding term loan with Silicon Valley Bank, including the principal balance of $25.0 million, interest of $148,000, an early prepayment fee of $500,000 and an end-of-term payment fee of $625,000. Due to the early termination of the facility, management estimates the company will save a total of $2.0 million in cash interest payments over the remaining term of the original facility.

Conference Call and Webcast

The company has scheduled a conference call for 4:30 p.m. Eastern (1:30 p.m. Pacific) today, August 10, to discuss second-quarter financial results and key strategic achievements.

Interested participants can join the conference call using the following numbers:

U.S. Toll-Free Dial-In: +1-844-243-4690
International Dial-In: +1-225-283-0138
Passcode: 58692729

A live webcast of the conference call will be available on the [“Investors”][1] section of the Arcadia website at Following completion of the call, a recorded replay will be available on the company’s investor website.

Safe Harbor Statement

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying conference call contain forward-looking statements about the company and its products, including statements relating to components of the company’s long-term financial success; the company’s traits, commercial products, and collaborations; and the company’s ability to manage the regulatory processes for its traits and commercial products. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s and its partners’ ability to develop commercial products incorporating its traits and to complete the regulatory review process for such products; the company’s compliance with laws and regulations that impact the company’s business, and changes to such laws and regulations; and the company’s future capital requirements and ability to satisfy its capital needs. Further information regarding these and other factors that could affect the company’s financial results is included in filings the company makes with the Securities and Exchange Commission from time to time, including the section entitled “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2016. These documents are on the SEC Filings section of the [Investor Relations pages][1] of the company’s website at [][2]. All information provided in this release and in the attachments is as of the date hereof, and Arcadia Biosciences, Inc. undertakes no duty to update this information.

About Arcadia Biosciences, Inc.

Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA) develops agricultural products that create added value for farmers while benefitting the environment and enhancing human health. Arcadia’s agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salinity Tolerance, Heat Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia’s nutrition traits and products are aimed at creating healthier ingredients and whole foods with lower production costs. For more information, visit [][2].

Arcadia Biosciences, Inc.

Condensed Consolidated Balance Sheets


(In thousands, except share data)

June 30,


December 31, 2016
Current assets:

Cash and cash equivalents

$ 13,438 $ 2,013

Short-term investments

30,740 48,547

Accounts receivable

432 349

Unbilled revenue

141 184

Inventories — current

286 252

Prepaid expenses and other current assets

1,480 877

Total current assets

46,517 52,222
Property and equipment, net 417 508
Inventories — noncurrent 1,153 1,327
Long-term investments 2,498
Other noncurrent assets 346 19
Total assets $ 48,433 $ 56,574
Liabilities and stockholders’ equity
Current liabilities:

Accounts payable and accrued expenses

$ 1,834 $ 2,359

Amounts due to related parties

27 30

Notes payable  — current


Unearned revenue — current

666 740

Total current liabilities

6,694 3,129
Notes payable — noncurrent 21,058 25,127
Unearned revenue — noncurrent 2,920 3,120
Other noncurrent liabilities 3,000 3,000
Total liabilities 33,672 34,376
Stockholders’ equity:

Common stock, $0.001 par value—150,000,000 and 400,000,000
   shares authorized as of June 30, 2017 and December 31, 2016;
   42,664,821 and 44,487,678 shares issued and outstanding as of
   June 30, 2017 and December 31, 2016

43 44

Additional paid-in capital

174,503 173,723

Accumulated deficit

(159,772 ) (151,550 )

Accumulated other comprehensive loss

(13 ) (19 )

Total stockholders’ equity

14,761 22,198
Total liabilities and stockholders’ equity $ 48,433 $ 56,574

Arcadia Biosciences, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss


(In thousands, except share and per share data)

Three Months Ended June 30,

Six Months Ended

June 30,

2017 2016 2017 2016


$ 195 $ 65 $ 400 $ 320


103 140 209 292

Contract research and government grants

693 516 1,400 961

Total revenues

991 721 2,009 1,573
Operating expenses:

Cost of product revenues

116 35 222 182

Research and development

1,669 2,216 3,492 4,418

Selling, general and administrative

2,943 2,759 5,995 6,195

Total operating expenses

4,728 5,010 9,709 10,795
Loss from operations (3,737 ) (4,289 ) (7,700 ) (9,222 )
Interest expense (365 ) (327 ) (704 ) (654 )
Other income, net 104 76 200 152
Net loss before income taxes (3,998 ) (4,540 ) (8,204 ) (9,724 )
Income tax provision (8 ) (11 ) (18 ) (17 )
Net loss and net loss attributable to common
$ (4,006 ) $ (4,551 ) $ (8,222 ) $ (9,741 )
Net loss per share attributable to common stockholders:

Basic and diluted

$ (0.09 ) $ (0.10 ) $ (0.19 ) $ (0.22 )
Weighted-average number of shares used in per
   share calculations:

Basic and diluted

42,664,821 44,308,245 43,572,936 44,274,508
Other comprehensive income, net of tax

Unrealized gains on available-for-sale


7 25 6 109
Other comprehensive income 7 25 6 109
Comprehensive loss attributable to common
$ (3,999 ) $ (4,526 ) $ (8,216 ) $ (9,632


Arcadia Biosciences, Inc.

Condensed Consolidated Statements of Cash Flows


(In thousands)

Six Months Ended June 30,
2017 2016
Net loss $ (8,222 ) $ (9,741 )
Adjustments to reconcile net loss to cash used in operating activities:

Depreciation and amortization

146 147

Gain on disposal of equipment

(3 )

Net amortization of investment premium and discount

(65 ) 139

Stock-based compensation

760 393

Accretion of debt discount

99 98

Changes in operating assets and liabilities:

Accounts receivable

(83 ) 529

Unbilled revenue

43 (10 )


140 (19 )

Prepaid expenses and other current assets

(603 ) (670 )

Other noncurrent assets

(327 ) (67 )

Accounts payable and accrued expenses

(525 ) 195

Amounts due to related parties

(3 ) (4 )

Unearned revenue

(274 ) 163

Net cash used in operating activities

(8,917 ) (8,847 )
Proceeds from sale of property and equipment 4
Purchases of property and equipment (58 ) (198 )
Purchases of investments (19,405 )
Proceeds from sales and maturities of investments 39,785 12,205

Net cash provided by investing activities

20,326 12,007
Payments of debt issuance costs (46 )
Proceeds from exercise of stock options and ESPP purchases 16 273

Net cash provided by financing activities

16 227
Net increase in cash and cash equivalents 11,425 3,387
Cash and cash equivalents — beginning of period 2,013 23,973
Cash and cash equivalents — end of period $ 13,438 $ 27,360
Cash paid for interest $ 599 $ 474
Cash paid for income taxes $ 1 $ 2
Exchange of membership interest in unconsolidated entity for common stock $ 2 $
Stock option exercise cost included in accounts receivable $ $ 30